dupplicates |
a list containing the names of patients that are believed to be dulicates across datasets |
E.MTAB.386 |
Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. |
GSE12418 |
Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. |
GSE12470 |
Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis. |
GSE13876 |
Survival-related profile, pathways, and transcription factors in ovarian cancer. |
GSE14764 |
A prognostic gene expression index in ovarian cancer - validation across different independent data sets. |
GSE17260 |
Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. |
GSE18520 |
A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. |
GSE19829 |
Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. |
GSE20565 |
A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer. |
GSE2109 |
IGC EXpression Project for Oncology |
GSE26193 |
miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. |
GSE26712 |
A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. |
GSE30009 |
Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. |
GSE30161 |
Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance. |
GSE32062 |
High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. |
GSE32063 |
High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. |
GSE44104 |
COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer. |
GSE49997 |
Validating the impact of a molecular subtype in ovarian cancer on outcomes: a study of the OVCAD Consortium. |
GSE51088 |
POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer. |
GSE6008 |
Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. |
GSE6822 |
Classification of ovarian tumor samples |
GSE8842 |
Analysis of gene expression in early-stage ovarian cancer. |
GSE9891 |
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. |
loadOvarianEsets |
Function to load ovarian cancer expression sets from the Experiment Hub |
PMID15897565 |
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. |
PMID17290060 |
An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. |
PMID19318476 |
Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. |
TCGA.RNASeqV2 |
Integrated genomic analyses of ovarian carcinoma. |
TCGAOVARIAN |
Integrated genomic analyses of ovarian carcinoma. |